Cargando…

The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity

Mucosal nasal vaccine development, although ideal to protect from pathogens invading mucosally, is limited by the lack of specific adjuvant. We recently used P1, a conserved region of HIV-1 gp41-envelope glycoprotein, as efficient antigen in a prophylactic HIV-1 mucosal vaccine applied nasally. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Lin, Tudor, Daniela, Bomsel, Morgane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886812/ https://www.ncbi.nlm.nih.gov/pubmed/33613520 http://dx.doi.org/10.3389/fimmu.2020.599278

Ejemplares similares

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41
por: Duchemin, Maxence, et al.
Publicado: (2020)

The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
por: Khamassi, Marwa, et al.
Publicado: (2020)

Peptide P5 (residues 628–683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection
por: Yu, Huifeng, et al.
Publicado: (2008)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
por: Bomsel, Morgane, et al.
Publicado: (2023)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
por: Mayer-Blackwell, Koshlan, et al.
Publicado: (2022)

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
por: Cottignies-Calamarte, Andréa, et al.
Publicado: (2023)

Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1
por: Mühle, Michael, et al.
Publicado: (2017)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

IL-7-Adjuvanted Vaginal Vaccine Elicits Strong Mucosal Immune Responses in Non-Human Primates
por: Logerot, Sandrine, et al.
Publicado: (2021)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies
por: Ma, Ben-Jiang, et al.
Publicado: (2011)

Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission
por: Mariotton, Jammy, et al.
Publicado: (2021)

Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates
por: Bekri, Selma, et al.
Publicado: (2017)

Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission
por: Ramakrishnan, Rajesh, et al.
Publicado: (2006)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
por: Joshi, Vinita R., et al.
Publicado: (2020)

Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles
por: Kumar, Sonu, et al.
Publicado: (2021)

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice
por: Van Roey, Griet A, et al.
Publicado: (2012)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
por: Raman, Suresh C., et al.
Publicado: (2019)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan
por: Jafri, Syyada Samra, et al.
Publicado: (2012)

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
por: Ruiz, Maria Julia, et al.
Publicado: (2022)

The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1(+) lymph node macrophages
por: Park, Chung, et al.
Publicado: (2015)

Innate Lymphoid Cells in Mucosal Immunity
por: Panda, Santosh K., et al.
Publicado: (2019)

The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody
por: Tudor, Daniela, et al.
Publicado: (2010)

Immunisation with the membrane proximal external region of gp41 of HIV-1 grafted into the transmembrane envelope protein of a gammaretrovirus
por: Strasz, N, et al.
Publicado: (2012)

Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan
por: Jafri, Syyada Samra, et al.
Publicado: (2012)

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein
por: Qiu, Jiayin, et al.
Publicado: (2019)

Anti-gp41 antibodies inhibit infection and transcytosis of HIV-1 infectious molecular clones expressing transmitted/founder envelopes
por: Jain, S, et al.
Publicado: (2012)

Maternal Envelope gp41 Ectodomain-Specific Antibodies Are Associated With Increased Mother-to-Child Transmission of Human Immunodeficiency Virus-1
por: Naiman, Nicole E, et al.
Publicado: (2020)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Editorial: Platelet and megakaryocyte dysfunctions in infectious diseases
por: Assinger, Alice, et al.
Publicado: (2023)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
por: Yang, Zheng, et al.
Publicado: (2018)

Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus
por: Smyth, Mark, et al.
Publicado: (2021)

Editorial: The Role of Innate Lymphoid Cells in Mucosal Immunity
por: Borger, Jessica G., et al.
Publicado: (2020)

The initial interplay between HIV and mucosal innate immunity
por: Caputo, Valeria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hmvcke9nhq0tef2fslnto0cfon